Eye drops with a caspase-9 inhibitor prevent retinal injury from retinal vein occlusion. In the left image, RVO causes swelling in the retina and the retinal layers are less distinct. In the right image, the eye drops have restored the distinct layers of the retina. (Troy lab)
Researchers at Columbia University Irving Medical Center have developed eye drops that could prevent vision loss after retinal vein occlusion, a major cause of blindness for millions of adults worldwide.
A study, in mice, suggests that the experimental therapy—which targets a common cause of neurodegeneration and vascular leakage in the eye—could have broader therapeutic effects than existing drugs.
The study was published in Nature Communications.
What is Retinal Vein Occlusion?
Retinal vein occlusion occurs when a major vein that drains blood from the retina is blocked, usually due to a blood clot. As a result, blood and other fluids leak into the retina, damaging specialized light-sensing neurons called photoreceptors.
Standard treatment for the condition currently relies on drugs that reduce fluid leakage from blood vessels and abnormal blood vessel growth. But there are significant drawbacks. These therapies require repeated injections directly into the eye, and for the patients who brave this daunting prospect, the treatment ultimately fails to prevent vision loss in the majority of cases.
The new treatment targets an enzyme called caspase-9, says Carol M. Troy, MD, PhD, professor of pathology & cell biology and of neurology in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at Columbia University Vagelos College of Physicians and Surgeons, who led the studies. Under normal conditions, caspase-9 is believed to be primarily involved in programmed cell death, a tightly regulated mechanism for naturally eliminating damaged or excess cells.
In studies of mice, the Troy lab discovered that when blood vessels are injured by retinal vein occlusion, caspase-9 becomes uncontrollably activated, triggering processes that can damage the retina.
Eye Drops Prevent Retinal Injury
The Troy lab found that a highly selective caspase-9 inhibitor, delivered in the form of eye drops, improved a variety of clinical measures of retinal function in a mouse model of the condition. Most importantly, the treatment reduced swelling, improved blood flow, and decreased neuronal damage in the retina.
“We believe these eye drops may offer several advantages over existing therapies,” says Troy. “Patients could administer the drug themselves and wouldn’t have to get a series of injections. Also, our eye drops target a different pathway of retinal injury and thus may help patients who do not respond to the current therapy.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Retinal vein occlusion
- Retinal Vein Occlusion (RVO) Market 2021-2030: Prominent Treatment Providers Include Allergan, Novartis and Regeneronon July 1, 2021 at 11:15 am
The "Retinal Vein Occlusion - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ...
- Retinal Vein Occlusion: Global Outlook and Current and Emerging Treatment Practices 2021on June 29, 2021 at 8:23 pm
The "Retinal Vein Occlusion - Market Insight, Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. This 'Retinal Vein Occlusion - Market Insights, Epidemiology, ...
- Global Retinal Vein Occlusion Market Insights to 2030 - ResearchAndMarkets.comon June 28, 2021 at 9:51 am
The “Retinal Vein Occlusion - Market Insight, Epidemiology and Market Forecast - 2030” report has been added to ResearchAndMarkets.coms ...
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149on June 26, 2021 at 1:02 am
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, today ...
- Retina Research Center Offers Clinical Trials For Macular Degeneration And Moreon June 25, 2021 at 12:52 pm
Studio 512 Co-Host Stephanie Gilbert spoke with a panel of doctors at Retina Research Center. The panel included Dr. Berger, Dr. Makkouk, Dr. Brent, Dr. Whiteside, and Ivana Gunderson.
Go deeper with Google Headlines on:
Retinal vein occlusion
Go deeper with Bing News on:
- 5-minute breathing workout matches vascular benefits of exerciseon July 1, 2021 at 10:50 pm
Strength training is a well-established way to boost the capabilities of the body's many muscle groups, and the same may well be true of those that facilitate breathing. A new study has provided the ...
- Peripheral Vascular Devices Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2028on June 30, 2021 at 10:11 pm
Selbyville, Delaware According to the research report titled 'GLOBAL Peripheral Vascular Devices Market 2021-2028', available with Market Study Report LLC, global peripheral vascular devices market is ...
- Tackling Vein Disease With a Modern Approach, Interview With Dr. Rajiv Agarwalon June 28, 2021 at 7:00 am
In June 2021, Dr. Rajiv Agarwal, board-certified cardiologist at Modern Heart and Vascular Institute, talked about vein disease on Great Day Houston. He elaborated ...
- Avinger Announces Key Opinion Leader Presentations at Vascular Conferences in Germanyon June 28, 2021 at 6:31 am
REDWOOD CITY, CA / ACCESSWIRE / June 28, 2021 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...
- Modern Vascular Announces Hiring of Dr. Steve Berkowitzon June 28, 2021 at 5:00 am
Modern Vascular, a pioneering medical group dedicated to preventing amputation through the treatment of peripheral artery disease (PAD), today announced the hiring of Dr.